Guardant Health Inc (NAS:GH)
$ 29.54 0 (0%) Market Cap: 3.61 Bil Enterprise Value: 3.83 Bil PE Ratio: 0 PB Ratio: 52.66 GF Score: 70/100

Guardant Health Inc at Cowen HealthCare Conference Transcript

Mar 03, 2020 / 02:20PM GMT
Release Date Price: $74.01 (-5.21%)
Doug Schenkel
Cowen and Company, LLC, Research Division - MD & Senior Research Analyst

All right. Good morning. It's our pleasure to welcome Helmy Eltoukhy, and Derek Bertocci from -- Derek Bertocci, excuse me, from Guardant Health. Guardant Health is a molecular diagnostic company that provides comprehensive genomic profiling and other services to clinical and biopharmaceutical customers. We believe Guardant's liquid biopsy panels are well positioned to outpace tissue-based competitors due to the advantages of blood-based profiling and Guardant's strong supporting data and commercial prowess. Over the next 25 to 30 minutes, we're going to talk about the 2020 outlook, progress with reimbursement and regulation, an update on G360 commercial efforts and on this growing traction amongst biopharmaceutical partners. If we have time, we hope to close with a discussion of pipeline developments and associated timelines for LUNAR.

Questions & Answers

Doug Schenkel
Cowen and Company, LLC, Research Division - MD & Senior Research Analyst

So thanks,

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot